{"id":"rixubis","rwe":[{"pmid":"33303707","year":"2020","title":"Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea.","finding":"","journal":"Blood research","studyType":"Clinical Study"},{"pmid":"32866032","year":"2020","title":"Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.","finding":"","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","studyType":"Clinical Study"},{"pmid":"32816519","year":"2020","title":"Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.","finding":"","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","studyType":"Clinical Study"},{"pmid":"30799297","year":"2019","title":"[Factor IX assays in treated hemophilia B patients].","finding":"","journal":"Annales de biologie clinique","studyType":"Clinical Study"},{"pmid":"29999951","year":"2006","title":"Coagulation Factor IX.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Baxalta now part of Shire","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Dysgeusia","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"","severity":"common","organSystem":""},{"effect":"Positive furin antibody test","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[]},"trials":[],"aliases":["Coagulation Factor IX [Recombinant]","BAX 326","Recombinant factor IX","BAX326","rFIX"],"company":"Baxalta now part of Shire","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=RIXUBIS","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:00:12.490245+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:00:24.191622+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RIXUBIS","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:00:25.252301+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor IX exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:00:25.902454+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109205/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:00:25.807078+00:00"}},"allNames":["rixubis"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Rixubis is a small molecule that binds to a specific target, but the exact nature of this interaction and the resulting pharmacological effects are not publicly available."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=rixubis","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rixubis","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:28:14.419595","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:00:27.669009+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"rixubis","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":["Hemophilia B"],"enrollment":6,"completionDate":"2022-05-11"},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":["Hemophilia B"],"enrollment":25,"completionDate":"2021-08-11"},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":["Hemophilia"],"enrollment":310,"completionDate":"2020-06-30"},{"nctId":"NCT01488994","phase":"PHASE2,PHASE3","title":"BAX 326 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-20","conditions":["Hemophilia B"],"enrollment":23,"completionDate":"2013-05-14"},{"nctId":"NCT01174446","phase":"PHASE3","title":"Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-07-29","conditions":["Hemophilia B"],"enrollment":86,"completionDate":"2012-05-03"},{"nctId":"NCT01507896","phase":"PHASE3","title":"BAX 326 Surgery Study in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-19","conditions":["Hemophilia B"],"enrollment":30,"completionDate":"2014-05-15"},{"nctId":"NCT02922231","phase":"","title":"Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-01-06","conditions":["Hemophilia B"],"enrollment":57,"completionDate":"2019-04-04"},{"nctId":"NCT02190149","phase":"","title":"Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2014-07-22","conditions":["Hemophilia A","Hemophilia B"],"enrollment":64,"completionDate":"2016-03-29"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL2109205"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Baxalta now part of Shire","relationship":"Original Developer"}],"publicationCount":12,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Baxalta now part of Shire","recentPublications":[{"date":"2020 Dec 31","pmid":"33303707","title":"Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea.","journal":"Blood research"},{"date":"2020 Jan-Dec","pmid":"32866032","title":"Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis"},{"date":"2020 Jan-Dec","pmid":"32816519","title":"Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis"},{"date":"2019 Feb 1","pmid":"30799297","title":"[Factor IX assays in treated hemophilia B patients].","journal":"Annales de biologie clinique"},{"date":"2006","pmid":"29999951","title":"Coagulation Factor IX.","journal":""}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"RIXUBIS","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:00:27.669009+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}